300519.SZ Stock Analysis
30
Avoid
Based on Eyestock quantitative analysis, 300519.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicine and health food. The company is headquartered in Shaoxing, Zhejiang and currently employs 316 full-time employees. The company went IPO on 2016-06-24. The main products of the Company are cardiovascular and cerebrovascular diseases medicine as well as traumatic disease medicine. Its other products include the drugs used in respiratory systems, digestive systems, urinary systems, paediatric diseases and immune systems. The firm operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.